Haemophilia B News and Research

RSS

Lack of hemophilia treatment in the developing world costing lives

When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives.

16 Nov 2009

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences, a company focused on misfolded protein diseases, today reported its second quarter operating results and provided an update on the Company's diagnostic and therapeutic programs.

13 Nov 2009

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

Research supports world blood donor day message on blood safety

Other countries could learn from the mistakes made in UK blood policy concludes research awarded by the Economic and Social Research Council's Michael Young Prize.

13 Jun 2009

Discovery of gene mutation which causes epilepsy and mental retardation - but only in women

An Australian and British research team have discovered a gene mutation that causes epilepsy and mental retardation but only in women.

12 May 2008

Guidelines for von Willebrand disease diagnosis and management

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

4 Mar 2008

New guidelines for von Willebrand disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

1 Mar 2008

Irish Government launches program to provide life insurance to people with HIV, Hep C through contaminated blood products

The Irish government on Thursday launched a program to provide life insurance, mortgage protection and travel insurance to people who contracted HIV or hepatitis C through contaminated blood products, Ireland's Evening Echo reports (Evening Echo, 9/27).

2 Oct 2007

EDMA welcomes 7 new members

EDMA, the European Diagnostic Manufacturers Association, enlarges its membership with six new companies: BioSystems SA, Diagnostica Stago, Innogenetics, Luminex Corporation, Orion Diagnostica and Tecan, and the Foundation for Innovative New Diagnostics (FIND).

9 Jan 2007

Ground-breaking discoveries that provide hope of an alternative treatment option for haemophilia sufferers

Haemophilia is a hereditary blood disease, primarily affecting males, where the blood fails to clot causing potentially life-threatening 'bleeds'. About one in 6000 Australian males is born with haemophilia in severe, moderate or mild form. People with haemophilia rely on intravenous infusion of recombinant Factor VIII clotting protein.

11 Aug 2005

Gene therapy used to successfully treat haemophilia in dogs

Progress in gene therapy to treat haemophilia has been impressive in the past few years. Gene therapy has been used to successfully treat haemophilia in dogs.

9 Aug 2005

Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week’s BMJ.

19 May 2005

Mutations in the HFE gene directly associated with chronic joint disease

Mutations in the HFE gene, which is involved in iron regulation, seem to be directly associated with chronic joint disease (or haemophilic arthropathy) among haemophilic patients, claim a team of Portuguese scientists in the April issue of the journal Blood.

4 Apr 2005

Steps to minimise the risk of onward transmission of vCJD

Selected groups of patients are this week being notified about the results of a risk assessment exercise for blood plasma products.

22 Sep 2004

John Reid has announced further developments concerning variant Creutzfeldt-Jakob disease

He told MPs in a written ministerial statement that an exercise has begun to notify some recipients of blood products about the results of a risk assessment exercise carried out by the Health Protection Agency.

10 Sep 2004

Genetically modified fish may help treat hemophiliacs

A human blood-clotting factor used to treat some people with haemophilia and accident victims suffering serious bleeding has been produced using genetically modified fish.

9 Sep 2004

The Australian Government response to Senate inquiry into hepatitis C and blood supply

Although the Inquiry found that decision makers had made reasonable decisions in the 80s, based on the evidence available, medically acquired hepatitis C has hurt many people.

30 Aug 2004

Oxford Biomedica to win Department of Health gene funding

Oxford spinout Oxford Biomedica was yesterday awarded £0.5 million by the Department of Health to conduct the first British gene therapy haemophilia trial.

31 Mar 2004

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government

Haemophilia Society President to challenge government for second time in Lords question on proposed Hepatitis C ex gratia payment scheme On Thursday 25 March, the first business in the House of Lords will be further questioning of Ministers by the Haemophilia Society’s President, Lord Morris of Manchester.

27 Mar 2004